FDA approves drug targeting mutated KRAS proteins for pancreatic cancer

The Food and Drug Administration granted regulatory approval for daraxonrasib, a oral medication targeting mutated KRAS proteins in pancreatic cancer. In clinical trials, the drug extended median survival times beyond 13 months, effectively doubling the life expectancy compared to conventional chemotherapy.